恶性淋巴瘤患者接受替沙仑赛输注后纤维蛋白溶解受抑导致相对高凝状态
这项前瞻性队列研究在单中心纳入25例接受替沙仑赛治疗的成人弥漫大B细胞淋巴瘤患者,于淋巴细胞清除化疗前及CAR-T输注后第3天和第13天采集外周血分析凝血/纤溶参数。除1例外所有患者均发生细胞因子释放综合征(CRS),13例需托珠单抗治疗;CRS发生时总PAI-1显著升高,伴纤溶受抑的相对高凝状态,CRS缓解后逐渐恢复。
要点
- CAR-T输注后除1例外均发生CRS,13例需托珠单抗治疗。
- CRS发生时总PAI-1显著升高,提示纤维蛋白溶解受抑。
- 该相对高凝状态在CRS缓解后逐渐恢复,未观察到器官损伤。
核心结论
- 即使发生轻度CRS的弥漫大B细胞淋巴瘤患者,在CRS发生时也观察到伴总PAI-1显著升高的纤溶受抑和相对高凝状态。
- 研究结果有助于理解CRS相关凝血病,并强调CAR-T治疗期间监测系列凝血/纤溶参数的重要性。
研究设计与样本
- 前瞻性队列研究,在单中心纳入25例接受替沙仑赛治疗的成人弥漫大B细胞淋巴瘤患者。
- 于淋巴细胞清除化疗前及CAR-T输注后第3天和第13天共3个时间点采集外周血样本。
主要发现
- 除1例外所有患者输注后发生CRS,13例需要托珠单抗治疗。
- 总PAI-1平均水平在淋巴细胞清除化疗前为22.5 ng/mL,第3天为41.0 ng/mL(P = .02)。
- 可溶性纤维蛋白平均水平在基线为3.16 µg/mL,第3天为8.04 µg/mL,第13天为9.16 µg/mL(P < .01)。
- 第13天总PAI-1平均水平为25.1 ng/mL。
- CRS缓解后纤溶受抑所致相对高凝状态逐渐消退,总PAI-1恢复至输注前水平,未观察到器官损伤。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has facilitated progress in treatment of refractory/relapsed diffuse large B-cell lymphoma (DLBCL). A well-known adverse event after CAR-T therapy is cytokine release syndrome(CRS). However, the etiology and pathophysiology of CRS-related coagulopathy remain unknown. Therefore, we conducted a prospective cohort study to comprehensively analyze coagulation/ fibrinolysis parameters present in peripheral blood of adult DLBCL patients treated with tisagenlecleucel in a single institution. Samples were collected from 25 patients at 3 time points: before lymphocyte-depletion chemotherapy and on days 3 and 13 after CAR-T infusion. After infusion, all patients except 1 experienced CRS, and 13 required the administration of tocilizumab. A significant elevation in the plasma level of total plasminogen activator inhibitor 1 (PAI-1), which promotes the initial step of coagulopathy (mean, 22.5 ng/mL before lymphocyte-depletion and 41.0 on day 3, P = .02), was observed at the onset of CRS. Moreover, this suppressed fibrinolysis-induced relatively hypercoagulable state was gradually resolved after CRS remission with normalization of total PAI-1 to preinfusion levels without any organ damage (mean values of soluble fibrin: 3.16 µg/mL at baseline, 8.04 on day 3, and 9.16 on day 13, P < .01; and mean PAI-1: 25.1 ng/mL on day 13). In conclusion, a hypofibrinolytic and relatively hypercoagulable state concomitant with significant total PAI-1 elevation was observed at the onset of CRS even in DLBCL patients with mild CRS. Our results will facilitate understanding of CRS-related coagulopathy, and they emphasize the importance of monitoring sequential coagulation/fibrinolysis parameters during CAR-T therapy.
引用
- Yamasaki-Morita M, Arai Y, Ishihara T, et al. Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma. Blood Adv. 2022. PMID: 35580321. doi:10.1182/bloodadvances.2022007454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。